You are here

Africa

Despite Aid Push, Ebola Is Raging in Sierra Leone

NEW YORK TIMES   By Jeffrey Gettleman                        Nov.28, 2014

KISSI TOWN, Sierra Leone-- ...While health officials say they are making headway against the Ebola epidemic in neighboring Liberia, the disease is still raging in Sierra Leone, despite the big international push. In November alone, the World Health Organization has reported more than 1,800 new cases in this country, about three times as many as in Liberia, which until recently had been the center of the outbreak....

On Freetown’s outskirts, burly youth are setting up roadblocks. The police are nowhere to be found. The young men barricade the road brandishing digital thermometers. Credit Daniel Berehulak for The New York Times

Country / Region Tags: 
General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Scientists: 'Positive' results in 1st human trial of experimental Ebola vaccine

CNN -- By Laura Smith-Spark                              Nov. 27, 2014

The first human trial of an experimental Ebola vaccine has produced promising results, U.S. scientists said, raising hopes that protection from the deadly disease may be on the horizon.

All 20 healthy adults who received the vaccine in a trial run by researchers from the National Institutes of Health in Maryland produced an immune response and developed anti-Ebola antibodies, the NIH said Wednesday.

None suffered serious side effects, although two people developed a brief fever within a day of vaccination.

The vaccine is being developed by the NIH's National Institute of Allergy and Infectious Diseases and British pharmaceutical giant GlaxoSmithKline. The process has been fast-tracked in light of the current catastrophic Ebola outbreak in West Africa, which has claimed more than 5,000 lives.

http://www.cnn.com/2014/11/27/health/ebola-outbreak/

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Sierra Leone Seeks U.S. Military Help to Fight Ebola

         

Health workers spray themselves with chlorine disinfectants after removing the body a woman who died of Ebola virus in the Aberdeen district of Freetown, Sierra Leone, October 14, 2014.  Credit: Reuters/Josephus Olu-Mammah

reuters.com - by Emma Farge - November 26, 2014

(Reuters) - Sierra Leone appealed to the United States on Wednesday to send military aid to help it battle Ebola as it falls behind its West African neighbors Guinea and Liberia in the fight against the virus.

The worst recorded Ebola outbreak has killed at least 5,689 people, the World Health Organization said on Wednesday, as the virus has overwhelmed African countries with weak infrastructure and healthcare systemS.

(READ COMPLETE ARTICLE)

 

Country / Region Tags: 
General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Ebola discoverer Piot sees long, bumpy road to ending epidemic

REUTERS      By Kate Kelland                                                                                                  Nov. 26, 2014

LONDON --West Africa's Ebola epidemic could worsen further before abating but new infections should start to decline in all affected countries by the end of this year, a leading specialist on the disease said on Wednesday.

Peter Piot, one of the scientists who first identified the Ebola virus almost 40 years ago, said the outbreak was far from over, but said that "thanks to now massive efforts at all levels" what had been an exponential growth in numbers should soon begin to recede.

The death toll in the worst Ebola epidemic on record has risen to 5,459 out of 15,351 cases identified in eight countries by November 18, latest data from the World Health Organization (WHO) showed. Almost all those cases are in Guinea, Sierra Leone and Liberia.

"By the end of the year we should start seeing a real decline everywhere," Piot, who is now director of the London School of Hygiene and Tropical Medicine, told a meeting of public health experts, non-governmental organizations and officials.

http://www.reuters.com/article/2014/11/26/us-health-ebola-piot-idUSKCN0JA1AQ20141126

Country / Region Tags: 
General Topic Tags: 
Problem, Solution, SitRep, or ?: 

As Ebola Pingpongs In Liberia, Cases Disappear Into The Jungle

NATIONAL PUBLIC RADIO   By Kelly Mcevers                                                  Nov. 25, 2014
There's a new phase of Ebola in Liberia. Epidemiologists call it pingponging.

A rural health clinic about five hours outside Monrovia, Liberia. The clinic has a few rooms and no electricity.Kelly       McEvers/NPR

Back in March, the disease was found in the rural areas. Then as people came to the capital to seek care, it started growing exponentially there. Now, some sick people are going back to their villages, and the disease has pingponged to the rural areas again.

Read complete story and hear broadcast

http://www.npr.org/blogs/goatsandsoda/2014/11/25/366381386/as-ebola-ping-pongs-in-liberia-cases-disappear-into-the-jungle

Country / Region Tags: 
General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Government accused of failing to provide emergency care for British ebola volunteers

THE TELEGRAPH   By Colin Freeman                                                                                         Nov. 26, 2014British medics who have volunteered to fight the Ebola outbreak in Sierra Leone have accused the Government of failing to offer them proper emergency back-up if they get infected.

The government is planning to despatch up to 1,500 NHS volunteers to the west African nation over coming months, as part of a £125m aid programme that a force of 800 British troops began rolling out last month.

But officials have refused to guarantee that any medic who catches the virus will be flown back to Britain for treatment, insisting that most cases can be dealt by a British army clinic that has been set up in the capital, Freetown.

The ruling has caused disquiet among some medics, who point out that the British army facility is not equipped with either kidney dialysis machines or artificial lungs, both of which could be necessary for treatment of anyone with advanced Ebola symptoms.

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Saving lives without new drugs

SCIENCE        By Jon Cohen                                                                                         Nov. 21, 2014

...Just a handful of basic interventions to fight the killer effects of Ebola, including dehydration and secondary infections, could dramatically lower the CFR there, says Michael Callahan, an infectious disease specialist at Massachusetts General Hospital in Boston..

With so much room for improvement in supportive care, the current international focus on drugs is “misguided,” says Callahan, who has recently worked in Monrovia and provided care in four previous Ebola outbreaks. “While we wait for months for forthcoming experimental therapies, many lives can be saved, certainly hundreds and possibly thousands, using inexpensive and simple therapies,” he says.

Callahan is helping an international team develop guidelines dubbed Maximum Use of Supportive Therapy (MUST), aimed at keeping more patients alive. It includes intravenous (IV) drips to replace massive fluid loss from diarrhea and vomiting, a risk factor for shock; balancing of electrolytes such as calcium or potassium, which prevents kidney and heart failure; nasogastric tubes for feeding; and testing and treatment of secondary infections such as malaria. Introducing MUST will also make it easier to study new treatments, Callahan says...

Country / Region Tags: 
General Topic Tags: 
Problem, Solution, SitRep, or ?: 

The Race for an Ebola Vaccine

Description of efforts by the big drug companies to develop an Ebloa vaccine
THE NEW YORKER    By Vauhine Vara                        Nov. 25, 2014

"...why this race to create an Ebola vaccine among Merck, GlaxoSmithKline, and Johnson & Johnson—three of the world’s biggest drug manufacturers? For years, pharmaceutical companies didn’t invest much in vaccines, partly because they were so costly and complicated to produce: they’re often made out of live bacteria, which are notoriously difficult to work with. But, over the past several years, companies have realized that the difficulties of making vaccines could be an asset, because they can make it more difficult for generic-drug companies to create copycat versions than for prescription drugs. The vaccine market has also been growing more quickly than the prescription-drug market. The World Health Organization estimates, based on various sources, that global vaccine sales rose from five billion dollars in 2000 to twenty-four billion dollars last year...."

Read complete article
http://www.newyorker.com/business/currency/race-ebola-vaccine

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Projected Impact of Vaccination Timing and Dose Availability on the Course of the 2014 West African Ebola Epidemic

PLOS CURRENT OUTBREAKS                                                                              Nov. 21, 2014
By David Fisman and Ashleigh Tuite, Dalla Lana School of Public Health, University of Toronto

As removal of population-level susceptibility through vaccination could be a highly impactful control measure for this epidemic, we sought to estimate the number of vaccine doses and timing of vaccine administration required to reduce the epidemic size. Our base model was fit using the IDEA approach, a single equation model that has been successful to date in describing Ebola growth. We projected the future course of the Ebola epidemic using this model. Vaccination was assumed to reduce the effective reproductive number. We evaluated the potential impact of vaccination on epidemic trajectory under different assumptions around timing of vaccine availability.

Country / Region Tags: 
General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Here’s How the Ebola Vaccine Trial Is Doing

TIME MAGAZINE By Alexandra Sifferlin                          Nov. 25, 2014
 By  Alexandra Sifferlin                       

Scientists are scurrying to get their Ebola vaccines through the necessary safety trials before they can be used widely. That includes the University of Maryland School of Medicine, which recently kicked off the latest step in their research: figuring out the appropriate dosing for the vaccine that’s both effective and safe.

The University of Maryland is one of a handful of institutions involved in the testing of an experimental but promising vaccine developed by the National Institutes of Health’s Vaccine Research Center (VRC) and GlaxoSmithKline (GSK). The hope is that the vaccine will pass through early trials needed by end of December so that the World Health Organization (WHO) and a panel of outside experts can decide whether to move on to a large efficacy trial, which would mean vaccinating a lot of people in West Africa to see how well it works.

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Pages

Subscribe to Africa
howdy folks